Prevention of a first stroke: A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association

JAMA

Volumn 281, Issue 12, 1999, Pages 1112-1120

  Gorelick, Philip B ^a   Sacco, Ralph L ^b   Smith, Don B ^c   Alberts, Mark ^d   Mustone Alexander, Lisa ^e   Rader, Dan ^f   Ross, Joyce L ^f   Raps, Eric ^f   Ozer, Mark N ^g   Brass, Lawrence M ^h   Malone, Mary E ⁱ   Goldberg, Sheldon ^j   Booss, John ^k   Hanley, Daniel F ^l   Toole, James F ^m   Greengold, Nancy L ⁿ   Rhew, David C ⁿ  

^a RUSH MEDICAL COLLEGE   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

^c Colorado Neurological Institute ^*  (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Jefferson Community College   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k DEPARTMENT OF VETERANS AFFAIRS   (United States)

^l JOHNS HOPKINS HOSPITAL   (United States)

^m WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ALCOHOL CONSUMPTION; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CIGARETTE SMOKING; DIABETES MELLITUS; DIET; DYSLIPIDEMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICAL INFORMATION; MEDICAL LITERATURE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0033620379     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.12.1112     Document Type: Review

References (128)

1. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998;29:415-421.
2. National Stroke Association. Stroke/Brain Attack Briefing. Englewood, Colo: Postgraduate Institute for Medicine; 1996:1-34.
3. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996;27:1459-1466.
4. Gorelick PB. Stroke prevention. Arch Neurol. 1995; 52:347-355.
5. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB, for the The Framingham Study. Stroke risk profile: adjustment for antihypertensive medication. Stroke. 1994; 25:40-43.
6. Davis PH, Dambrosia JM, Schoenberg BS, et al. Risk factors for ischemic stroke: a prospective study in Rochester, Minnesota. Ann Neurol. 1987;22:319-327.
7. Gorelick PB. Stroke prevention: an opportunity for efficient utilization of health care resources during the coming decade. Stroke. 1994;25:220-224.
8. National Heart, Lung, and Blood Institute. Fact Book Fiscal Year 1996. Bethesda, Md: US Deptof Health and Human Services, National Institutes of Health; 1997.
9. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157: 2413-2446.
10. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action: a statement for healthcare professionals. Circulation. 1997;95:1085-1090.
11. Evidence-Based Medicine Working Group. Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA. 1992;268:2420-2425.
12. Woolf SH. Practice guidelines: a new reality in medicine, I: recent developments. Arch Intern Med. 1990;150:1811-1818.
13. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1989;95(suppl 2):2S-4S.
14. Matchar DB, McCrory DC, Barnett HJ, Feussner JR. Medical treatment for stroke prevention. Ann Intern Med. 1994;121:41-53.
15. Canadian Task Force on the Periodic Health Examination. The periodic health examination. CMAJ. 1979;121:1193-1254.
16. Preventive Services Task Force. Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. Baltimore, Md: Williams & Wilkins;1996;xcii, 953.
17. Eccles M, Freemantle N, Mason J, for the North of England Aspirin Guideline Development Group. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. BMJ. 1998;316:1303-1309.
18. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995; 25:305-313.
19. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
20. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
21. Biller J, Feinberg WM, Castaldo JE, et al. Guidelines for carotid endarterectomy: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation. 1998;97:501-509.
22. Hall WD, Ferrario CM, Moore MA, et al. Hypertension-related morbidity and mortality in the southeastern United States. Am J Med Sci. 1997;313:195-209.
23. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27:373-380.
24. Messerli F, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? a systematic review. JAMA. 1998; 279:1903-1907.
25. 4th American College of Chest Physicians Consensus Conference on Antithrombotic Therapy, Tucson, Arizona, April 1995, Proceedings. Chest. 1995; 108(suppl 4):225S-522S.
26. Tanne D, Goldbourt U, Zion M, Reicher-Reiss H, Kaplinsky E, Behar S, for The SPRINT Study Group. Frequency and prognosis of stroke/TIA among 4808 survivors of acute myocardial infarction. Stroke. 1993; 24:1490-1495.
27. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-257.
28. Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW, Sutton GC. Antithrombotic agents in coronary artery disease. Chest. 1998;114:611-633.
29. Albers GW, Easton JD, Sacco RL, Teal P. Anti-thrombotic and thrombolytic therapy for ischemic stroke. Chest 1998;114:683-698.
30. Ryan TJ, Anderson JL, Antman EM, et al, for the Committee on Management of Acute Myocardial Infarction. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 1996;28:1328-1428.
31. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990;323:147-152.
32. Report of the Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet. 1980;2:989-994.
33. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet. 1994;343:499-503.
34. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulation therapy in patients with non-rheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5-10.
35. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
36. Sacks FM, Pfeffer MA, Moye LA, et al, for the Choj lesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
37. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (45). Lancet. 1994; 344:1383-1389.
38. The LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol. 1995;76:474-479.
39. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643-1650.
40. Gorelick PB, Mazzone T. Plasma lipids and stroke. J Cardiovasc Risk. In press.
41. Gorelick PB, Schneck M, Berglund LF, Feinberg W, Goldstone J. Status of lipids as a risk factor for stroke. Neuroepidemiology. 1997;16:107-115.
42. Sacco RL, Benjamin EJ, Broderick JP, et al. American Heart Association Prevention Conference, IV: prevention and rehabilitation of stroke, risk factors. Stroke. 1997;28:1507-1517.
43. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Summary of the second report of the National Cholesterol Education Program (NCEP). JAMA. 1993;269:3015-3023.
44. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
45. Wolf PA, Dawber TR, Thomas HEJ, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology. 1978;28:973-977.
46. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114:579-589.
47. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: stroke prevention in patients with nonvalvular atrial fibrillation. Neurology. 1998;51:671-673.
48. Hart RG, Sherman DG, Easton JD, Cairns JA. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology. 1998;51:674-681.
49. Prystowsky EN, Benson DWJ, Fuster V, et al, from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Management of patients with atrial fibrillation: a statement for healthcare professionals. Circulation. 1996;93:1262-1277.
50. The Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials. Arch Intern Med. 1997;157:1237-1240.
51. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
52. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest. 1995;108(suppl 4):352S-359S.
53. Singer DE. Anticoagulation to prevent stroke in atrial fibrillation and its implications for managed care. Am J Cardiol. 1998;81:35C-40C.
54. Howard PA, Duncan PW. Primary stroke prevention in nonvalvular atrial fibrillation: implementing the clinical trial findings. Ann Pharmacother. 1997;31: 1187-1196.
55. Wheeldon NM, Tayler Dl, Anagnostou E, Cook D, Wales C, Oakley GD. Screening for atrial fibrillation in primary care. Heart. 1998;79:50-55.
56. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995;155:277-281.
57. Monette J, Gurwitz JH, Rochon PA, Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc. 1997;45: 1060-1065.
58. Bucher HC, Griffith LE, Guyatt GH. Effect of HMG-coA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1998; 128:89-95.
59. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke. 1997;28:946-950.
60. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997;278:313-321.
61. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke. 1997;28:2315-2320.
62. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation. 1995;91: 2274-2282.
63. American Diabetes Association Clinical practice recommendations 1998. Diabetes Care. 1998;21 (suppl 1):S1-S89.
64. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
65. The Canadian Guide to Clinical Preventive Health Care. Ottawa, Ontario: Canada Communication Group Publishing; 1994.
66. Findlay JM, Tucker WS, Ferguson GG, et al. Guidelines for the use of carotid endarterectomy: current recommendations from the Canadian Neurosurgical Society. CMAJ. 1997;157:653-659.
67. Scottish Intercollegiate Guidelines Network. Management of patients with stroke: management of carotid stenosis and carotid endarterectomy: a national clinical guideline recommended for use in Scotland. Available at: http//pc47.cee.hw.ac.uk/sign/ clinical.htm. Accessed April 1998.
68. American College of Physicians. Guidelines for medical treatment for stroke prevention. Ann Intern Med. 1994;121:54-55.
69. Perry JR, Szalai JP, Norris JW, for the Canadian Stroke Consortium. Consensus against both endarterectomy and routine screening for asymptomatic carotid artery stenosis. Arch Neurol. 1997;54:25-28.
70. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA. 1995;273: 402-407.
71. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. Physical activity and cardiovascular health. JAMA. 1996;276:241-246.
72. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-318.
73. Kuller LH, Dorman JS, Wolf PA. Cerebrovascular diseases and diabetes. In: National Diabetes Data Group Department of Health and Human Services, National Institutes of Health, ed. Diabetes in America: Diabetes Data Compiled for 1984; Bethesda, Md; National Institutes of Health, 1985:1-18.
74. Karem JH. Diabetes mellitus. In: Tierney LH, McPhee SJ, Papdakis MA, eds. Current Medical Diagnosis & Treatment. Stamford, Conn: Appleton & Lange; 1996.
75. Scottish Intercollegiate Guidelines Network. Management of diabetic cardiovascular disease: a national clinical guideline. Available at: http:// pc4.cee.hw.ac.uk/clinical.htm. Accessed April 1998.
76. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
77. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75: 894-903.
78. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet. 1998;352:837-853.
79. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
80. Lorenz R. The problem with intensive therapy. Diabetes Care. 1998;21:2021-2022.
81. Norris JW, Zhu CZ, Bornstein NM, Chambers BR. Vascular risks of asymptomatic carotid stenosis. Stroke. 1991;22:1485-1490.
82. Howard G, Baker WH, Chambless LE, et al, for Asymptomatic Carotid Atherosclerosis Study Investigators. An approach for the use of Doppler ultrasound as a screening tool for hemodynamically significant stenosis (despite heterogeneity of Doppler performance): a multicenter experience. Stroke. 1996; 27:1951-1957.
83. Barnett HJ, Eliasziw M, Meldrum HE. The identification by imaging methods of patients who might benefit from carotid endarterectomy. Arch Neurol. 1995;52:827-831.
84. Strandness DE Jr. Angiography before carotid endarterectomy. Arch Neurol. 1995;52:832-833.
85. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995;273: 1421-1428.
86. Abbott RD, Yin Y, Reed DM, Yano K. Risk of stroke in male cigarette smokers. N Engl J Med. 1986;315: 717-720.
87. Colditz GA, Bonita R, Stampfer MJ, et al. Cigarette smoking and risk of stroke in middle-aged women. N Engl J Med. 1988;318:937-941.
88. Gorelick PB, Rodin MB, Langenberg P, Hier DB, Costigan J. Weekly alcohol consumption, cigarette smoking, and the risk of ischemic stroke: results of a case-control study at three urban medical centers in Chicago, Illinois. Neurology. 1989;39:339-343.
89. Bonita R, Scragg R, Stewart A, Jackson R, Beaglehole R. Cigarette smoking and risk of premature stroke in men and women. BMJ. 1986;293:6-8.
90. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ. 1989; 298:789-794.
91. Howard G, Wagenknecht LE, Burke GL, et al, for the The Atherosclerosis Risk in Communities (ARIC) Study. Cigarette smoking and progression of atherosclerosis. JAMA. 1998;279:119-124.
92. Sacco RL, Roberts JK, Boden-Albala B, et al, for the The Northern Manhattan Stroke Study. Race-ethnicity and determinants of carotid atherosclerosis in a multiethnic population. Stroke. 1997;28:929-935.
93. Mast H, Thompson JL, Lin IF, et al. Cigarette smoking as a determinant of high-grade carotid artery stenosis in Hispanic, black, and white patients with stroke or transient ischemic attack. Stroke. 1998;29:908-912.
94. Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol. 1991;134:250-256.
95. O'Leary DH, Polak JF, Kronmal RA, et al, for the The CHS Collaborative Research Group. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. Stroke. 1992;23:1752-1760.
96. Wolf PA. Cigarettes, alcohol, and stroke. N Engl J Med. 1986;315:1087-1089.
97. Donahue RP, Abbott RD, Reed DM, Yano K. Alcohol and hemorrhagic stroke: The Honolulu Heart Program. JAMA. 1986;255:2311-2314.
98. Gorelick PB. The status of alcohol as a risk factor for stroke. Stroke. 1989;20:1607-1610.
99. Gill JS, Zezulka AV, Shipley MJ, Gill SK, Beevers DG. Stroke and alcohol consumption. N Engl J Med. 1986;315:1041-1046.
100. Thornton J, Symes C, Heaton K. Moderate alcohol intake reduces bile cholesterol saturation and raises HDL cholesterol. Lancet. 1983;2:819-822.
101. Pellegrini N. Pareti FI, Stabile F, Brusamolino A, Simonetti P. Effects of moderate consumption of red wine on platelet aggregation and haemostatic variables in healthy volunteers. Eur J Clin Nutr. 1996;50: 209-213.
102. Fletcher GF. Exercise in the prevention of stroke. Health Rep. 1994;6:106-110.
103. Kokkinos PF, Narayan P, Colleran JA, et al. Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. N Engl J Med. 1995;333:1462-1467.
104. Blair SN, Kampert JB, Kohl HW, et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA. 1996;276:205-210.
105. Manson JE, Rimm EB, Stampfer MJ, et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet. 1991;338:774-778.
106. Lakka TA, Salonen JT. Moderate to high intensity conditioning leisure time physical activity and high cardiorespiratory fitness are associated with reduced plasma fibrinogen in eastern Finnish men. J Clin Epidemiol. 1993;46:1119-1127.
107. Wang JS, Jen CJ, Chen HI. Effects of exercise training and deconditioning on platelet function in men. Arteriosder Thromb Vasc Biol. 1995;15:1668-1674.
108. Rangemark C, Hedner JA, Carlson JT, Gleerup G, Winther K. Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep. 1995;18:188-194.
109. Williams PT. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med 1996;334:1298-1303.
110. Stamler J, Rose G, Stamler R, Elliott P, Dyer A, Marmot M. INTERSALT study findings: public health and medical care implications. Hypertension. 1989; 14:570-577.
111. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286-291.
112. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In: Francis RB, ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York, NY: Marcel Dekker; 1998:183-236.
113. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995; 274:1049-1057.
114. Gillman MW, Cupples LA, Gagnon D, et al. Protective effect of fruits and vegetables on development of stroke in men. JAMA. 1995;273:1113-1117.
115. Gey KF, Stahelin HB, Eichholzer M, for the Basel Prospective Study. Poor plasma status of carotene and vitamin C is associated with higher mortality from ischemic heart disease and stroke. Clin Invest. 1993; 71:3-6.
116. Khaw KT, Barrett-Connor E. Dietary potassium and stroke-associated mortality: a 12-year prospective population study. N Engl J Med. 1987;316:235-240.
117. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ, for the Framingham Study. Cigarette smoking as a risk factor for stroke. JAMA. 1988;259: 1025-1029.
118. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risk of stroke in women. JAMA. 1993;269:232-236.
119. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T, for the Agency for Health Care Policy and Research. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. JAMA. 1997;278:1759-1766.
120. Hurt RD, Sachs DP, Clover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195-1202.
121. Burt VL, Culter JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26:60-69.
122. Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J. 1995;130:572-579.
123. Macharia WM, Leon C, Rowe BH, Stephenson BJ, Haynes RB. An overview of interventions to improve compliance with appointment keeping for medical services. JAMA. 1992;267:1813-1817.
124. Devine EC, Reifschneider E. A meta-analysis of the effects of psychoeducational care in adults with hypertension. Nurs Res. 1995;44:237-245.
125. Mullen PD, Simons-Morton DC, Ramirez G, Frankowski RF, Green LW, Mains DA. A metaanalysis of trials evaluating patient education and counseling for three groups of preventive health behaviors. Patient Educ Couns. 1997;32:157-173.
126. An Indexed Bibliography on Self-Management for People With Chronic Disease. Washington, DC: Center for the Advancement of Health; 1996.
127. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996;348:383-386.
128. Roth HP, Caron HS, Hsi BP Estimating a patient's cooperation with his regimen. Am J Med Sci. 1971;262:269-273.